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Background: Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and demyelinating disease of
the central nervous system (CNS). Several cytokines are thought to be involved in the regulation of MS
pathogenesis. We recently identified interleukin (IL)-9 as a cytokine reducing inflammation and protecting from
neurodegeneration in relapsing–remitting MS patients. However, the expression of IL-9 in CNS, and the
mechanisms underlying the effect of IL-9 on CNS infiltrating immune cells have never been investigated.
Methods: To address this question, we first analyzed the expression levels of IL-9 in post-mortem cerebrospinal
fluid of MS patients and the in situ expression of IL-9 in post-mortem MS brain samples by immunohistochemistry.
A complementary investigation focused on identifying which immune cells express IL-9 receptor (IL-9R) by flow
cytometry, western blot, and immunohistochemistry. Finally, we explored the effect of IL-9 on IL-9-responsive cells,
analyzing the induced signaling pathways and functional properties.
Results: We found that macrophages, microglia, and CD4 T lymphocytes were the cells expressing the highest
levels of IL-9 in the MS brain. Of the immune cells circulating in the blood, monocytes/macrophages were the most
responsive to IL-9. We validated the expression of IL-9R by macrophages/microglia in post-mortem brain sections of
MS patients. IL-9 induced activation of signal transducer and activator of transcription (STAT)1, STAT3, and STAT5
and reduced the expression of activation markers, such as CD45, CD14, CD68, and CD11b in inflammatory
macrophages stimulated in vitro with lipopolysaccharide and interferon (IFN)-γ. Similarly, in situ the number of
activated CD68+ macrophages was significantly reduced in areas with high levels of IL-9. Moreover, in the same
conditions, IL-9 increased the secretion of the anti-inflammatory cytokine, transforming growth factor (TGF)-β.
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Conclusions: These results reveal a new cytokine expressed in the CNS, with a role in the context of MS. We have
demonstrated that IL-9 and its receptor are both expressed in CNS. Moreover, we found that IL-9 decreases the
activation state and promotes the anti-inflammatory properties of human macrophages. This mechanism may
contribute to the beneficial effects of IL-9 that are observed in MS, and may be therapeutically potentiated by
modulating IL-9 expression in MS.
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Interleukin (IL)-9 is a cytokine involved in the develop-
ment of allergic response and in immune responses
against intestinal nematodes [1, 2]. The involvement of
IL-9 in human autoimmunity has been studied in psoria-
sis, where it was shown that IL-9 receptor (IL-9R) is in-
creased in lesioned compared to healthy skin [3], and in
lupus erythematous, where IL-9 was reported to be
highly expressed in the serum [4]. We recently demon-
strated an important immunoregulatory role of IL-9 in
relapsing–remitting (RR) multiple sclerosis (MS), where
the expression levels in the cerebrospinal fluid (CSF) of
RR-MS patients inversely correlate with indexes of in-
flammatory activity, neurodegeneration, and disability
progression of MS [5]. Here, we characterize, for the first
time, the expression of IL-9 in the central nervous sys-
tem (CNS) of secondary progressive MS patients.
IL-9-induced cell responses are mediated by the IL-9R.
This heterodimeric receptor is composed of a specific alpha
chain and a gamma chain that it shares with the IL-2 recep-
tor. The binding of IL-9 with its receptor promotes cross-
phosphorylation of Janus kinase (JAK) 1 [6] and JAK3 [6],
thus leading to activation of signal transducer and activator
of transcription (STAT) 1, 3, and 5 [7].
The downstream effects of IL-9 have been primarily
described in mast cells in the context of allergic re-
sponses. However, the effect of IL-9 on other immune
cell types and under different contexts is yet to be stud-
ied. In fact, a systematic analysis of IL-9R expression
among blood cells has never been performed. Here, we
conduct a comparative study of IL-9R expression by the
different immune cell types composing the human
blood. Our analysis reveals that monocytes express the
highest levels of IL-9R, suggesting they are the most re-
sponsive immune cells to IL-9. Accordingly, previous
studies demonstrated that human monocytes and alveo-
lar macrophages are affected by IL-9. Specifically, these
studies demonstrated that IL-9 reduced the respiratory
burst and inflammatory cytokine release [8, 9].
However, the role of IL-9 on resident macrophages or
those infiltrating the CNS has never been investigated. It is
known that under physiological conditions, resident micro-
glia is involved in host defense, immune regulation, tissue
homeostasis, and regeneration [10, 11]. Upon inflammatoryor pathological injury, blood monocyte-derived macrophages
infiltrate the CNS and support microglia in driving and con-
trolling the immune responses. Thus, under chronic CNS in-
flammation, macrophages become particularly relevant, and
dysregulation of macrophage functions may underlay the
pathogenesis of many CNS diseases, including MS.
Stimulated macrophages adopt context-dependent
phenotypes that either promote or inhibit inflammatory
responses. In fact, depending on the microenvironmental
signals of the local milieu, macrophages show a
spectrum of activated phenotypes that in vitro could be
simulated by using pro-inflammatory and anti-
inflammatory polarization assay [12, 13].
Thus, microglia/macrophages are multifunctional cells,
and the dynamic balance between pro- and anti-
inflammatory functions is crucial in MS and its mouse
model: experimental autoimmune encephalomyelitis
(EAE). The disturbance of this balance has a key role in
lesion pathogenesis and activity, and therefore in disease
progression [14].
Our study revealed that IL-9, expressed in active le-
sions of MS, might modulate inflammatory macrophage
properties in the CNS. Collectively these results could
lead to novel therapeutic strategies aimed at reverting
the pathogenic macrophage dysregulation in MS.
Methods
Neuropathology study on post-mortem MS brain samples
Immunohistochemistry and immunofluorescence
Snap frozen tissue blocks from 10 post-mortem brains
of secondary progressive MS patients and of 3 post-
mortem controls with non-inflammatory neurological
conditions were analyzed. The brains were obtained in
autopsy at the UK MS Society Tissue Bank at Imperial
College, under ethical approval by the National Research
Ethics Committee (08/MRE09/31). Serial fresh sections
(10-μm thick) were immunostained with myelin oligo-
dendrocyte glycoprotein (MOG) or major histocompati-
bility complex (MHC) class II antibodies for
neuropathological assessment of lesion presence and ac-
tivity following previously published procedures [15]. In
addition, to validate the activity stage of the lesion,
double staining with MHC class II and MOG antibodies
was also performed. Serial frozen sections, cut from the
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rabbit polyclonal antibody or anti-IL-9R mouse mono-
clonal antibody. We performed double immunohisto-
chemistry (IHC) and immunofluorescence (IF) staining,
combining antibodies specific for IL-9 and markers
CD68, TMEM119, and MHC class II. For MOG, IL-9R,
CD68 immunostaining treatment with cold methanol
was performed, whereas for HLA (DP, DQ, DR), IL-9
and TMEM119 was used ethanol. Details of the anti-
bodies used for IHC and IF are reported in Table 1. Im-
ages, were acquired using an Axiophot microscope (Carl
Zeiss, Jena), equipped with a digital camera (Axiocam
MRC) and analyzed using the Axiovision 6 AC software.
Analysis of IL-9 production
CSF samples from 29 post-mortem MS patients (age 60,
2 ± 18,8; mean ± SD) and 17 age-matched controls (age
62, 6 ± 17,2; mean ± SD) with other neurological diseasesTable 1 Antibodies used for immunostainings
Primary
antibody
Fluorophore Origin Target
CX3CR1 FITC Rat (mAB; IgG2b) Chemokine C-X3-C rec
CD206 PE Mouse (mAB; IgG1) Mannose receptor
HLA-DP, DQ,
DR
BV785 Mouse (mAB;
IgG2a)
MHC class II antigen
CD11b PerCP-Cy5.5 Mouse (mAB; IgG1) Alpha M integrin
CD45 PE-Cy7 Mouse (mAB; IgG) Leukocyte common an
CD68 APC Mouse (mAB;
IgG2b)
CD68 110-kDa transme
glycoprotein
CD14 APC-
eFluor780
Mouse (mAB; IgG1) Leucine-rich repeat (LR
CD163 VioBlue Mouse (mAB; IgG1) Hemoglobin-haptoglo
receptor
IL-9R BV421 Mouse (mAB;
IgG2b,k)
Interleukin-9 receptor a
IL-9R PE Mouse (mAB; IgG1) Interleukin-9 receptor a
IgG1 Isotype PE Mouse –
IgG2b,k Isotype BV421 Mouse –
MOG – Rabbit (pAB; IgG) Myelin oligodendrocyt
HLA-DP, DQ,
DR
– Mouse (mAB; IgG1) MHC class II antigen
CD68 – Mouse (mAB; IgG1) CD68 110-kDa transme
glycoprotein
TMEM 119 – Rabbit (pAB; IgG) Transmembrane prote
IL-9 – Rabbit Interleukin-9
IL-9R – Mouse (mAB; IgG) Interleukin-9 receptor
CD4 – Mouse (mAB; IgG1) CD4+ T lymphocytes
CD8 – Mouse (mAB; IgG1) CD8+ T lymphocytes
List of antibodies used for immunohistochemistry, immunofluorescence, and flow cwere centrifuged to eliminate cells and cellular debris
and immediately stored at − 80 °C until analyzed. All
samples were processed using identical standardized
procedures using a Bio-Plex Multiplex Cytokine Assay
(Bio-Rad Laboratories), according to the procedures pre-
viously optimized [16]. Concentrations of IL-9 were cal-
culated according to a standard curve generated for each
target and expressed as pg/ml. When the concentrations
of the cytokines were below the detection threshold, they
were assumed to be 0 pg/ml.
In vitro study
Purification of monocytes from blood and in vitro
differentiation of macrophages
Peripheral blood mononuclear cells (PBMCs) were puri-
fied from buffy coats of healthy adult (range 20–65 years
of age) volunteer blood donors (independently of sex),
and three patients with RR-MS according to establishedDilution Source Application
eptor 1 1:160 Biolegend, California, USA FC
1:50 Beckman Coulter, California,
USA
FC
1:100 BD Bioscience FC
1:80 Biolegend, California, USA FC
tigen 1:100 Beckman Coulter, California,
USA
FC
mbrane 1:20 Miltenyi, Germany FC
R) protein 1:100 eBioscience FC
bin scavenger 1:100 Miltenyi, Germany FC
lpha 1:30 BD Bioscience FC
lpha 1:20 R&D Systems, Minnesota, USA FC
1:20 R&D Systems, Minnesota, USA FC
1:30 BD Bioscience FC
e glycoprotein 1:50 Proteintech, Manchester, UK IHC
1:50 Dako, Glostrup, Denmark IHC
mbrane 1:25 Dako, Glostrup, Denmark IHC
in 119 1:50 Atlas Antibodies, Bromma,
Sweden
IHC
1:50 Santa Cruz Biotechnology, INC. IHC/IF
1:50 MAB290; R&D Systems IHC
1:50 ThermoFisher, Rockford, USA IF
1:50 Dako, Glostrup, Denmark IF
ytometry
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(Amersham Pharmacia Biotech, Uppsala, Sweden).
Approval by the ethics committee of the Fondazione
Santa Lucia and written informed consent in accordance
with the Declaration of Helsinki from all participants
were obtained before study initiation.
CD14+ monocytes were purified by immunomagnetic
depletion using Easy Sep human monocyte enrichment
kit (Stem Cell). Purified monocytes CD14+ showed a
purity > 96%, as revealed by flow cytometry analysis
(data not shown). Monocytes were cultured at a density
of 500,000 cells/ml in 6-well plates (Falcon) in RPMI
1640 with 10% of Fetal Bovine Serum (FBS) and induced
to differentiate toward macrophages for 3 days in the
presence of M-CSF (50 ng/ml). At day 3 and 6, half of
the medium was changed with fresh medium and M-
CSF (25 ng/ml). At the end of the culture, the cells were
pre-incubated or not for 24 hours (h) with IL-9 (20 ng/
ml), before being cultured for further 48 h in the absence
of stimuli, or in the presence of Lipopolysaccharides
(LPS) (10 ng/ml) and Interferon (IFN)-γ (50 ng/ml) to
obtain pro-inflammatory macrophage subtype [18].
Flow cytometry analysis
Receptors expressed by macrophages were analyzed by
staining with mouse anti-human CX3CR1 (FITC),
CD206 (PE), HLA-DR (BrilliantViolet 785), CD163 (Vio-
Blue), CD11b (PerCP-Cy5.5), CD45 (PE-Cy7), CD68
(APC), CD14 (APC-eFluor780), IL-9R Subunit alpha (PE
or BrilliantViolet 421), Mouse IgG1 Isotype control (PE),
and Mouse IgG2b,k Isotype control (BrilliantViolet 421),
with Fixable Aqua Dead Cell Stain (Thermo Fisher
Scientific). Details of the antibodies used for flow
cytometry (FC) are reported in Table 1. Samples were
analyzed on a Cytoflex (Beckman Coulter), and data
were analyzed with FlowJo (Tree Star, Ashland, OR,
USA).
Analysis of cytokine production
IL-9, IL-6, TGF-β, and cytokines in culture supernatants
were measured by ELISA kits (eBioscience), IL-10 was
measured by ELISA kit (RnD Biosystems), IL-12 was
measured by a high sensitivity ELISA kit (RnD Biosys-
tems), IL-27 was measured by ELISA kit (My Bio-
source), and IL-35 was measured by ELISA kit
(Cloud-Clone Corporation), according to manufac-
turer’s instructions.
Western blot analysis
Protein extraction was performed as previously de-
scribed [5]. Membranes were incubated with the follow-
ing antibodies overnight at 4 °C: rabbit polyclonal anti-
human phospho-STAT1 (Y701) (Cell Signaling; 1:1000
dilution), rabbit polyclonal anti-human phospho-STAT3(Y705) (Cell Signaling; 1:1000 dilution), mouse IgG1
anti-human phospho-STAT5 (Y694) (BD Transduction
Laboratories; 1:500 dilution), rabbit polyclonal anti- hu-
man IL-9R (Abcam; 1:500 dilution), rabbit anti-human
alpha/beta tubulin (Cell Signaling; 1:1000 dilution), and
mouse anti-human actin (Abgent; 1:3000 dilution). All
antibodies were diluted in 3% non-fat dry milk in PBS,
containing 0.1% Tween-20. Secondary anti-mouse or
anti-rabbit IgGs conjugated to horseradish peroxidase
(Cell Signaling) were incubated with the membranes for
1 h at room temperature at a 1:2000–1:3000 dilution in
PBS containing 3% non-fat dry milk and 0.1% Tween 20.
Immunostained bands were detected by chemilumines-
cent method (SuperSignal West Pico PLUS ECL Sub-
strate, Thermo Scientific).Statistical analysis
For pair-wise comparisons of different conditions from
the same donors or different donors, we used a non-
parametric two-tailed paired or unpaired t test, respect-
ively. Two-way Analysis of Variance (ANOVA) was per-
formed to analyze the main effects of two conditions on
the dependent variables and their interactions. Data were
presented as mean ± standard error (SEM). The Pearson
correlation coefficient was used to assess the significance
of correlation among the count of CD68+ and IL-9+
cells. A p value (p) of less than 0.05 was considered sta-
tistically significant.Results
IL-9 is expressed in the central nervous system of
secondary progressive MS patients
To investigate the presence of IL-9 in the CNS of sec-
ondary progressive MS patients, IL-9 levels were mea-
sured in CSF obtained from post-mortem progressive
MS patients and compared with levels measured in CSF
from post-mortem non-neurological control subjects.
Significantly higher levels of IL-9 (fold increase = 9; p <
0.01) were found in the CSF of MS patients compared to
controls, indicating that IL-9 expression is upregulated
in the CNS of progressive MS patients (Fig. 1a).
Using immunohistochemistry techniques, we analyzed
post-mortem cerebral tissue from a subgroup of MS
brains and non-neurological control brains, from which
CSF samples were also analyzed. In 2 out of the 8 exam-
ined MS brain samples (Table 2; Fig. 1b–d), we found
IL-9 expression in scattered cells in normal appearing
(NA) white matter (WM). Comparing lesion types of
WM according to their activity, we localized increased
IL-9 expression mainly in pre-active (Fig. 1e–i) and in
active lesions (Fig. 1j–n). IL-9 was also found to be
expressed in some inactive lesions, however to a lesser
extent (Table 2).
Fig. 1 IL-9 is expressed in the central nervous system of secondary progressive MS patients. Molecular and neuropathological analysis of IL-9
expression in post-mortem MS white matter. CSF levels of IL-9 in the 29 post-mortem MS cases and 17 age-matched controls (a) (**p < 0.01). In
normal appearing white matter (NAWM) identified by myelin oligodendrocyte glycoprotein (MOG) immunostaining (b), rare and scattered IL-9+
cells with microglia morphology (c, d) were detected by immunohistochemistry or immunofluorescence. In pre-active white matter lesions (WML)
(e), where clusters of MHC class II+ microglia were present (arrowheads in g), increased expression of IL-9 was detected (f). Double
immunohistochemistry demonstrated that most of the IL-9 was expressed by clusters of microglia expressing MHC-II (arrowheads in h) or TMEM-
119 (i). In active WML, with on-going demyelination (j) and a high density of microglia/macrophages MHC-II+ (l), elevated IL-9 expression was
observed (k), often in combination with MHC-II (arrowheads in m) or TMEM-119 (n). Original magnifications: × 100 (b, e, g, h, l, k), × 200 (c, f, j–
m), ×400 (d, i, n)
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with the morphological characteristics of activated
microglia (Fig. 1d). In pre-active and active WM lesions
(WML) (Fig. 1e, j), a high density of IL-9+ cells was de-
tected in areas of elevated MHC class II reactivity
(Fig. 1f–h, k–m). A small proportion of IL-9+ cells were
found to express TMEM119, a marker of resident
microglia (Fig. 1i, n). Concerning gray matter (GM),
scarce IL-9+ cells were detected in NAGM (Table 2;
Fig. 2a, b) and more abundant IL-9+ cells in active and
chronic active GML among the examined MS cases
(Table 2; Fig. 2c–f). IL-9 was found to be expressed in
cells with microglia morphology in active GML of 3 out
of the 10 examined MS cases (Table 2, Fig. 2c–f).
Moreover, IL-9 was similarly expressed in cortical and
subcortical areas of the same brain sections, asdemonstrated by the immunostaining of active subpial and
active leukocortical GM lesions (Supplementary Fig. 1).
IL-9 was found to be highly expressed by a proportion
of meningeal inflammatory infiltrating cells (Fig. 2g, h)
within the cerebral sulci adjacent to the GM. By using
double immunofluorescence, IL-9+ cells in meningeal
and perivascular infiltrate were identified as CD4 T lym-
phocytes (Fig. 2i), while none expressed CD8 (Fig. 2j),
few IL9+ cells expressed the CD68, the marker of acti-
vated and macrophages (Supplementary Fig. 2).
Among the immune cells, monocytes and macrophages
expressed the highest levels of IL-9R
To identify which of the immune cells respond to IL-9,
we systematically tested the expression of IL-9R on
PBMCs obtained from healthy donors. We found the
Table 2 Individual clinical, autopsy, and neuropathology details in white matter and gray matter of secondary progressive MS
patients
Case MS 92 MS 121 MS 160 MS 180 MS 234 MS 286 MS 342 MS 356 MS 389 MS 473
Sex/age at death (years) F/38 F/49 F/44 F/44 F/39 M/45 F/35 F/45 F/55 F/39
Onset (years) 21 35 28 26 24 29 30 29 28 27
Disease duration (years) 17 14 16 18 15 16 5 16 27 12
Meningeal inflammation + – + + – + – – – –
Perivascular infiltration + + – – + + + – + –
IL-9+ in White matter NAWM – + – – – + – – – –
Pre-active – – – – ++ ++ – – – –
Active – – – – – – ++ ++ ++ ++
Chronic active + + – – – + – – – –
Remyelination – – + – + – – – – –
Inactive – – – – – + – – – –
IL-9+ in Gray matter NAGM – – – – – – – – – –
Pre-active – – – – – – – – – –
Active – – + – + + – – – –
Chronic active – + + – + + – – – –
Remyelination – – – – – – – – – –
Inactive – – – – + – – – – –
The degree of meningeal and perivascular inflammation was scored as −, absent; +, present; and ++, abundant. Similarly, the presence of IL-9 expressing (IL-9+)
cells in the different types of lesions was scored as: −, absent; +, present; and ++, abundant. Tissues are classified as follows: normal appearing white matter
(NAWM), normal appearing gray matter (NAGM), pre-active, chronic active, remyelination, and inactive
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tion, as demonstrated by flow cytometry (Fig. 3a, b) and
validated by western blot (Fig. 3c). In contrast, fewer
total lymphocytes (Fig. 3a–c), B lymphocytes, CD8 lym-
phocytes, mucosal associated invariant T cells (MAIT)
cells, natural killer (NK) cells, T helper cells, and T regu-
latory cells (Supplementary Fig. 3A,B) express IL-9R. Im-
portantly, monocytes from blood of MS patients express
similar levels of IL-9R compared to those of healthy do-
nors, indicating that monocytes may respond to IL-9
during MS disease (Fig. 3d).
Given the important distinction between “classical”
monocytes (CD14++CD16−) that migrate to sites of in-
jury where they differentiate into inflammatory macro-
phages [19], “intermediate” monocytes (CD14++CD16+)
that possess inflammatory characteristics [20], and “non-
classical” monocytes (CD14dimCD16++) that exhibit a
unique ability to patrol the resting vasculature and re-
move debris [21], we further characterized the expres-
sion of IL-9R on different classes of monocytes. We
found that classical and intermediate monocytes are the
immune cells most responsive to IL-9 (Fig. 3e, f).
Moreover, myeloid dendritic cells express higher levels
of IL-9R than plasmacytoid dendritic cells (Supplemen-
tary Fig. 4A, B). Next, we analyzed the expression of IL-
9R in monocyte-derived human macrophages. We found
that similar to freshly purified monocytes, all macro-
phage subtypes express IL-9R (Fig. 4a–c).IL-9R is expressed by macrophages in active MS lesions
In order to investigate the IL-9 responsiveness of resi-
dent CNS immune cells in MS, we analyzed immunohis-
tochemistry staining of IL-9R in post-mortem brain
tissues of MS patients. We found most of the IL-9R+
cells (Fig. 4g) in perivascular inflammatory infiltrates,
mainly in the white matter (Fig. 4d), in the presence of
diffuse microglia/macrophage activation (Fig. 4e) and in
areas containing IL-9+ cells (Fig. 4f). Double immuno-
fluorescence revealed that IL-9R is expressed by some
CD68+ macrophages/microglia in CNS (Fig. 4h, i) but
not by CD3+ T cells or CD20+ B cells (data not shown).
IL-9 reduces activation of human macrophages
Considering the responsiveness of macrophages to IL-9
and their relevance in the context of MS, we set to
examine how IL-9 affects macrophages.
In particular, we mimic the IL-9 stimulation that resident
or infiltrating macrophages receive in the CNS by using an
in vitro model of human macrophages differentiated from
blood monocytes of healthy donors, and stimulation with
recombinant IL-9. Then, we measured the resulting down-
stream phosphorylation of STAT1, 3, and 5. We found that
IL-9 induced phosphorylation of STAT1, 3, and 5, with
peak activation after 5min (Fig. 5a–c). Next, we used IFN-
γ + LPS to obtain inflammatory macrophages (Fig. 4a, c),
and we sought to determine whether IL-9 affects the activa-
tion of macrophages. To this end, we analyzed the
Fig. 2 IL-9 is expressed in gray matter lesions and meninges of secondary progressive MS patients. Neuropathological analysis of IL-9 expression
in post-mortem MS gray matter and meninges by immunohistochemistry and immunofluorescence. In normal appearing gray matter (NAGM) (a),
rare IL-9+ cells with microglia morphology were detected (b). In active gray matter lesions (GML) (c), in areas containing MHC class II+ cells with
microglia morphology (d), scattered IL-9+ were present (e, f), in particular in the external cortical layers close to the CSF surface or around small
blood vessels. High numbers of IL-9+ cells (h) were observed in meningeal infiltrates (g) overlying the cortical gray matter. Double
immunofluorescence for CD4 and IL-9 (i) or CD8 and IL-9 (j) of meningeal infiltrates in post-mortem brain tissues of progressive MS patients
demonstrated that CD4+ (arrowheads in i), but not CD8+, T lymphocytes express IL-9. Original magnifications: × 100 (a, c, d), × 200 (b, g, h), × 400
(e, f, i, j)
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surface as well as the cytokines released in their superna-
tants upon in vitro stimulation with exogenous recom-
binant IL-9. Although typical markers of the pro-
inflammatory or anti-inflammatory profiles, such as CX3CR1
and HLA-DR or CD206 and CD163, respectively, were not
modulated by IL-9 (Fig. 5d), IL-9 reduced inflammatory
properties of inflammatory macrophages, decreasing the ex-
pression of activation markers, such as CD45 (7.9%± 2.3),
CD11b (7.2%± 2.4), CD68 (16,5%± 3.3), and CD14 (13.3%±
3.6), reported here as percentage decrease (mean ± SEM) of
the mean fluorescence intensity (MFI) (Fig. 5e).
In order to analyze whether IL-9 expression is related
somehow to macrophage activation also in situ, westained 7 post-mortem MS brain tissues for the macro-
phage activation marker CD68 and for IL-9. By grouping
MS patients in group 1 characterized by high CD68 ex-
pression, and group 2 characterized by low CD68 ex-
pression, we found that patients in group 1 express low
levels of IL-9 (Fig. 6a), while patients in group 2 express
high levels of IL-9 (Fig. 6b). We found that the number
of IL-9 positive cells in group 1 and group 2 were signifi-
cantly different (Fig. 6c) and that the number of IL-9+
cells inversely correlates with number of CD68 positive
cells in the same brain tissue (Fig. 6d). The two groups
do not differ for any clinical and demographic param-
eter. However, the tissue blocks of CD68-high MS cases
examined in the current study present higher number
Fig. 3 IL-9R is widely expressed by human monocytes in the blood. IL-9R expression by monocytes and lymphocytes within peripheral blood
mononuclear cells (PBMC) of healthy donors was analyzed by flow cytometry. Plots from a representative experiment are shown (a). Graph
represents the frequency of monocyte and lymphocyte IL-9R+ cells, gated on PBMC (b). IL-9R expression was analyzed by western blot on sorted
monocytes and lymphocytes. Results from a representative donor and cumulative data of 3 donors are reported (c). IL-9R expression analyzed by
western blot on sorted monocytes from MS patients and healthy donors. Results from three representative donors of each group and cumulative
data are reported (d). IL-9R expression on classical (CD14++CD16−), intermediate (CD14++CD16+) and nonclassical (CD14dimCD16++) monocytes
gated on CD3- CD19- CD56- CD11c+ CD4+ cells was analyzed by flow cytometry. Plots from a representative experiment and cumulative graph
representing the frequency of monocyte subpopulation IL-9R+ cells (e). IL-9R expression was analyzed by western blot on sorted classical and
nonclassical monocytes. Results from a representative donor and cumulative data of 4 donors are reported (f). Mean ± SEM is shown for each
group. *p < 0.05, **p < 0.01, ***p < 0.001,****p < 0.0001 by paired Student’s t test (b, c, d, f) or by analysis of variance (e)
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the elevated degree of active demyelination in the sub-
group of CD68-high and IL-9-low MS cases.
IL-9 has an anti-inflammatory effect on human
macrophages
Although macrophages and inflammatory macrophages
(obtained with LPS + IFN-γ) do not produce detectable
levels of IL-9 (< 1.5 pg/ml), we investigated whether the
production of other cytokines was modulated by IL-9
stimulation.
We analyzed the anti-inflammatory cytokines TGF-β1,
by human macrophages stimulated with IL-9. We found
that TGF-β1 production was significantly increased
(67% ± 24; percentage increase pg/ml mean ± SEM),while the production of IL-10, IL-27, and IL-35 was not
affected by IL-9 (Fig. 7a).
In contrast, the pro-inflammatory cytokines IL-6, IL-
12, and IL-23 were not modulated by IL-9 (Fig. 7b).
These results are in line with a protective role of IL-9 in
MS and suggest that, at least in part, this protection is
mediated by an IL-9-induced reduction of macrophage
inflammatory properties and increase of TGF-β release.
Discussion
In MS, resident and infiltrating macrophages accumulate
in the brain and can exert both pro- or anti-
inflammatory activities or direct phagocytic myelin-
damaging activity [22], according to the pathological and
inflammatory conditions.
Fig. 4 In vitro and in situ macrophages are responsive to IL-9. Human blood classical monocytes (Cl. Mo) of healthy donors were differentiated in
macrophages (MΦ), and inflammatory macrophages (Infl. MΦ) in the presence of LPS and IFN-γ. IL-9R expression was analyzed by flow cytometry.
Plots from a representative experiment are shown (a). Graph represents the frequency of IL-9R+ cells (b). IL-9R expression was analyzed by
western blot. Results from a representative donor and cumulative data of 4 donors are reported (c). Mean ± SEM is shown for each group.
Neuropathological assessment of IL-9 and IL-9R expression in post-mortem MS brain. Areas of microglia activation (e) in white matter (d),
indicated with an asterisk, contain IL-9+ and IL-9R+ cells, mainly expressed in perivascular infiltrates (f, g). Scattered CD68+ IL-9R+ cells were found
in the white matter tissue (h, i). Original magnifications: × 100 (d, e), × 200 (f, g), × 400 (h, i)
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of progressive MS patients, that microglia and macrophages
respond to IL-9 in the brain, and that IL-9 regulates the
functional properties of human macrophages, shifting their
phenotype toward an anti-inflammatory profile.
The down-regulation of typical activation markers,
such as CD11b, CD14, CD68, and CD45, known to me-
diate important processes such as adhesion to endothe-
lium, migration, and phagocytosis [23–25], indicates that
IL-9 may reduce and regulate infiltration and phagocytic
activity of macrophages. Furthermore, we observed an
induction of the anti-inflammatory cytokine TGF-β1,
which is in line with the effect previously observed in
LPS-stimulated monocytes [9] and alveolar macrophages
[8]. Interestingly, in murine mast cells, the release of
mast cell protease-1 induced by IL-9 depends on TGF-β,
suggesting that mast cells may also produce TGF-β upon
IL-9 treatment [26]. This anti-inflammatory function of
IL-9 on macrophages could be relevant for the damping
of exaggerated inflammation, observed in autoimmune
diseases and even serve as target for future therapeutic
avenues. In particular, the IL-9 expression observed in
cortical lesions, both subpial and leukocortical, maysuggest a key role of IL-9 in regulating the inflammatory
events involved in neurodegeneration.
We previously reported that high levels of IL-9 in CSF
of RR-MS patients during the MS diagnosis are associ-
ated with lower disease progression over 4 years of clin-
ical follow-up [5]. Overall, these results support the
hypothesis that an intrinsic high expression of IL-9, be-
fore the disease establishment, correlates with a better
clinical profile of MS patients suggesting IL-9 as a prog-
nostic biomarker of better outcome of the disease. Even
if these data need to be validated in larger and independ-
ent MS cohorts, they are supported by recent data show-
ing that high IL-9 gene expression in the meninges is
associated with a subgroup of post-mortem progressive
MS patients with low levels of meningeal inflammation
and cortical demyelination, and a less severe and rapid
disease course [16]. Here, we report the presence of IL-9
protein in both CSF and CNS, particularly in pre-active
and active lesions, of the same examined post-mortem
progressive MS patients that indicates a consistent po-
tential beneficial effect of IL-9 not only in RR but also in
progressive MS disease. These data highlight the need to
better investigate and validate the potential value of CSF
Fig. 5 IL-9 activates STATs and reduces inflammatory properties in human macrophages. Human macrophages differentiated in vitro from blood
classical monocytes were stimulated with IL-9 (200 ng/ml) for 5, 10, and 20min and compared to unstimulated cells. The phosphorylation of
STAT1 (a), STAT3 (b), and STAT5 (c) was analyzed by western blot. Results from a representative donor and cumulative data of 3 donors are
reported. Mean ± SEM is shown for each group. *p < 0.05, by paired Student’s t test. Human macrophages differentiated as inflammatory
macrophages (Infl. MΦ) from blood classical monocytes of healthy donors (n = 18) were pretreated with IL-9 for 24 h and treated with specific
polarizing conditions for 48 h. The expression of CX3CR1, HLA-DR, CD206, CD163 (d), and CD45, CD68, CD14, CD11b (e) was analyzed by flow
cytometry. Data are reported as fold change with respect to macrophages (MΦ). Paired Student’s t test was used to compare different conditions.
*p < 0.05; **p < 0.01;***p < 0.001
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biomarker of a specific MS endophenotype with better
disease outcome and as marker to monitor responses to
therapies.
Given the IL-9 expression mainly associated to macro-
phages and activated microglia in WM and GM lesions,
these cells may represent the main cell sources of IL-9
found in the CSF of both RR- [5] and progressive MS
patients. However, the stimuli triggering IL-9 production
by microglia/macrophages in vivo and in vitro are not
known. The fact that IL-9 expression seems to bepresent both at time of diagnosis and during the disease
progression would indicate its possible involvement in
chronic inflammation characterizing MS. Further ana-
lysis of the specific molecular characterization of the tis-
sue resident and peripheral cells expressing IL-9, and of
the interacting inflammatory conditions/milieu, would
help to better understand potential useful therapeutic
targets.
In meningeal infiltrates of post-mortem progressive
MS patients, IL-9 is also expressed by CD4+ T lympho-
cytes. The latter corroborate previous findings that a
Fig. 6 IL-9 regulates macrophage activation in the brain of secondary progressive MS patients. Adjacent frozen sections of post-mortem brain of
progressive MS patients were stained with anti-CD68 and anti-IL-9 (1 representative of “CD68 high” group in a; 1 representative of “CD68 low”
group in b). Counts of total positive cells for IL-9 in brain biopsy specimens from 3 patients of “CD68 high” and 4 patients with “CD68 low” group
were compared. Mean ± SEM are reported (c). *p < 0.05. The count of IL-9 positive cells inversely correlated to CD68 positive cells with the
Pearson correlation (R, correlation coefficient)
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Th9 cells, are characterized by IL-9 production [27], in
response to a complex cytokine milieu. In fact, it is
known that in vitro lymphocytes, natural killer cells, and
mast cells [28] produce IL-9, particularly following ex-
posure to TGF-β and IL-4 [29]. However, we previously
reported that in vitro production of IL-9 by Th9 cells
obtained from CD4+ T lymphocytes stimulated with
TGF-β and IL-4 is similar in MS and healthy donors [5],
indicating that environmental conditions may influence
the in vivo induction of IL-9 by lymphocytes in the brain
of MS patients. In addition, our data help to characterize
inflammatory features of CD4+ T cells in meningeal in-
filtrates, suggesting that this cytokine may be involved in
intrathecal compartmentalization of MS inflammation,
in particular in the subarachnoid space.Several costimulatory signals provided by other inflam-
matory and antigen-presenting cells within the inflamma-
tory infiltrates, including the meningeal ones, may affect
the release and abundance of IL-9 in the CNS. In this con-
text, others and we previously demonstrated that OX40-
OX40-L interaction between antigen-presenting cells and
T cells could be involved in IL-9 induction [30, 31].
Further investigation of factors modulating IL-9 induc-
tion during MS, are needed. Moreover, IL-9 expression
may be influenced also by genetic and epigenetic modifi-
cations, which might explain the diversity of expression
levels among individuals, and correlate with the different
clinical outcomes of MS patients.
The functions related to IL-9 are mediated by its specific
receptor, IL-9R, known to be expressed on Th17 and Treg
cells, monocytes, and mast cells. Here, we demonstrate that
Fig. 7 IL-9 induces TGF-β production by human macrophages. TGF-β1, IL-10, IL-27, IL-35 (a), and IL-6, IL-12, IL-23 (b) production was analyzed in
the supernatants by ELISA. Paired Student’s t test was used to compare different conditions. *p < 0.05
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the same inflammatory infiltrates in which IL-9 is
expressed. Moreover, our detailed and systematic analysis
of IL-9R expression on human blood immune cells revealed
that classical monocytes (CD14++CD16−) and intermediate
monocytes (CD14++CD16+) express highest levels of IL-9R,
suggesting them as potential source of macrophages infil-
trated in the CNS and responsive to IL-9.
In contrast, nonclassical monocytes (CD14dim
CD16+), which are patrolling monocytes with a high
ability to migrate across endothelial monolayers [32]
and to remove damaged cells and debris from the
vasculature [21], express lower levels of IL-9R com-
pared to other monocytes. Similarly, plasmacytoid
dendritic cells, known for their induction of IL-10
producing T regulatory cells [33, 34], express lower
levels of IL-9R, compared to myeloid dendritic cells.
These results, together with the specificity of IL-9 ef-
fects on pro-inflammatory macrophages, suggest that
cells committed to resolve inflammation are less re-
sponsive to IL-9, likely due to an IL-9-mediated feed-
back control on inflammatory cells. Considering the
key role of macrophages in phagocytosis, antigen
presentation and lymphocyte stimulation, the orches-
trated expression of IL-9 and its receptor in MS pa-
tients may facilitate a specific immune response that
ameliorates the clinical outcome.Finally, these results highlight a new mechanism regu-
lating progressive MS disease and suggest either a poten-
tial good biomarker of disease inflammatory activity or a
novel approach for therapeutic intervention.
Moreover, the regulatory role played by IL-9 in human
inflammatory macrophages within the CNS, could be
relevant in other CNS disorders, including neurodegen-
erative diseases, such as Alzheimer, Parkinson, and
amyotrophic lateral sclerosis diseases [35], where even if
the pathological processes are not primarily inflamma-
tory driven, mononuclear phagocytes are known to con-
tribute to the development of pathology.
Conclusions
IL-9 is a new cytokine expressed by microglia and CD4+
T cells in lesions localized in both gray and white mat-
ter, as well as in inflamed meninges of MS patients, and
its receptor, IL-9R, is expressed by macrophages/micro-
glia in the areas IL-9+ of the CNS. We found that IL-9
downregulates macrophage activation via phosphoryl-
ation of STAT1, 3, and 5. This is a new immune mech-
anism that could regulate inflammation in CNS of
progressive MS patients. Given the absence of a therapy
for the progressive forms of MS and the unclear know-
ledge of the mechanisms leading to the pathology, these
findings could have important clinical therapeutic
implications.
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Additional file 1: Figure S1. IL-9 is expressed in subpial and leukortical
gray matter lesions of progressive MS cases. Active subpial gray matter le-
sion (GML) (A-C) and active leukocortical GML (D-F) of post-mortem brain
tissues of progressive MS patients were stained for myelin oligodendro-
cyte glycoprotein (MOG) (A,D), and IL-9 and analyzed by immunohisto-
chemistry (B,E) or immunofluorescence (C,F). Original magnifications: 100x
(A,D), 200x (B, E), 400x (C,F). Figure S2. Macrophages infiltrating the brain
of secondary progressive MS patients express IL-9. Double immunohisto-
chemistry for CD68 and IL-9 in post-mortem brain tissues of progressive
MS patients demonstrates that some CD68+ macrophages express IL-9
(A). Original magnifications: 100x (A), 400x (B). Figure S3. Human lym-
phocytes express low levels of IL-9R in the blood. IL-9R expression on B
lymphocytes, CD8+ lymphocytes, MAIT cells, NK cells, T regulatory cells
(A) and on T helper (Th) 1, Th1/Th17, Th17 and Th2 subsets was analyzed
by flow cytometry. Graph represents the frequency of lymphocyte sub-
population IL-9R+ cells (A, B). Mean ± SEM is shown for each group. Fig-
ure S4. Myeloid dendritic cells express higher levels of IL-9R compared
to plasmacytoid dendritic cells in the blood. IL-9R expression on plasma-
cytoid myeloid (CD4 + CD11c-) and myeloid (CD4 + CD11c+) dendritic
cells (pDC and mDC, respectively) gated on CD3-CD19-CD56-CD14-CD16-
cells of healthy donors’ PBMC was analyzed by flow cytometry. Graph
represents the frequency of IL-9R+ pDC and mDC cells (A). IL-9R expres-
sion was analyzed by Western blot on sorted pDC and mDC. Results from
a representative donor and cumulative data of 6 donors are reported (B).
Mean ± SEM is shown for each group.*p < 0.05.Abbreviations
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